Home » Stocks » OPNT

Opiant Pharmaceuticals, Inc. (OPNT)

Stock Price: $13.42 USD 0.43 (3.31%)
Updated Feb 24, 2021 3:27 PM EST - Market closed
After-hours: $13.60 +0.18 (1.34%) Feb 24, 4:37 PM
Market Cap 57.48M
Revenue (ttm) 27.37M
Net Income (ttm) -108,824
Shares Out 4.26M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 26.74
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $13.42
Previous Close $12.99
Change ($) 0.43
Change (%) 3.31%
Day's Open 13.00
Day's Range 12.99 - 13.67
Day's Volume 16,776
52-Week Range 6.79 - 14.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ...

Benzinga - 2 weeks ago

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) doses the first patient in a confirmatory pharmacokinetic (PK) study evaluating OPNT003 (nasal nalmefene) for opioid overdose treatment. Results from ...

GlobeNewsWire - 2 weeks ago

SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic...

GlobeNewsWire - 2 months ago

SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedica...

GlobeNewsWire - 2 months ago

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and ...

GlobeNewsWire - 2 months ago

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and ...

Insider Monkey - 2 months ago

In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insi...

Seeking Alpha - 3 months ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results. Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the est...

GlobeNewsWire - 3 months ago

SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and ...

GlobeNewsWire - 3 months ago

SANTA MONICA, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ...

GlobeNewsWire - 3 months ago

SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Ap...

GlobeNewsWire - 3 months ago

SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ...

GlobeNewsWire - 5 months ago

SANTA MONICA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and dru...

Seeking Alpha - 6 months ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions an...

GlobeNewsWire - 7 months ago

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and dru...

GlobeNewsWire - 8 months ago

SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone ...

Seeking Alpha - 9 months ago

Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and...

Seeking Alpha - 11 months ago

Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions an...

GlobeNewsWire - 1 year ago

SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions an...

Seeking Alpha - 1 year ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions an...

GlobeNewsWire - 1 year ago

SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and dr...

Seeking Alpha - 1 year ago

Based on our model, the value of Narcan Nasal Spray royalty alone should be worth anywhere from $11.6 to $27.5.

GlobeNewsWire - 1 year ago

SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and dru...

Seeking Alpha - 1 year ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call Transcript

Fox Business - 2 years ago

Trump takes on high drug prices

Opiant Pharmaceuticals CEO Roger Crystal on President Trump's calls to lower drug prices.

Other stocks mentioned: ABBV, GSK, JNJ, MRK, NVS, PFE, SNY, ZGNX

About OPNT

Opiant Pharmaceuticals, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in... [Read more...]

Industry
Biotechnology
Founded
2005
CEO
Dr. Roger Crystal
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
OPNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for OPNT stock is "Strong Buy." The 12-month stock price forecast is 41.33, which is an increase of 207.97% from the latest price.

Price Target
$41.33
(207.97% upside)
Analyst Consensus: Strong Buy